Findings

What do systematic reviews say?

2,261 questions · 2,280 findings · 114 reviews · Cystic Fibrosis and Genetic Disorders

Sort:Best matchNewestHighest certainty Download CSV

No studies found 856 · 37.5%GRADE not reported 58 · 2.5%Very low 550 · 24.1%Low 502 · 22%Moderate 271 · 11.9%High 43 · 1.9%

Medication management vs usual care

QoL

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 48 participants
Very low

Summary of findings: Comparison 3 ‐ deferiprone (DFP) vs deferoxamine

QoL

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1 participants
Very low

Deferasirox vs deferiprone (DFO)

Adherence to iron chelation therapy (%, SD)

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 452 participants
Very low

Deferasirox vs deferiprone (DFO)

SAEs ‐ thalassaemia‐related SAEs

It is very uncertain whether summary of findings: Comparison 2 ‐ deferasirox (DFX) changes SAEs Thalassaemia‐related SAEs compared with deferiprone (DFO) (very low certainty).

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
RR 0.95 [0.41, 2.17]
2 studies · 247 participants
Very low

Deferasirox vs deferiprone (DFO)

SAEs ‐ SCD‐related SAEs

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 195 participants
Very low

Deferasirox vs deferiprone (DFO)

All‐cause mortality

1 finding from 1 review

Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia 2023 · Cochrane Headline outcomes only
0.96 [0.06, 15.42]
2 studies · 240 participants
Very low

Hydroxyurea vs placebo

Reduction or prevention of kidney disease progression · people with sickle cell disease

1 finding from 1 review

Interventions for chronic kidney disease in people with sickle cell disease 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 142 participants
Very low

Angiotensin‐converting enzyme inhibitors vs vitamin C

Serious adverse events · children with sickle cell anaemia and microalbuminuria

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for chronic kidney disease in people with sickle cell disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Angiotensin‐converting enzyme inhibitors vs vitamin C

Mortality due to any cause · children with sickle cell anaemia and microalbuminuria

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for chronic kidney disease in people with sickle cell disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Angiotensin‐converting enzyme inhibitors vs vitamin C

Quality of life · children with sickle cell anaemia and microalbuminuria

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for chronic kidney disease in people with sickle cell disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hydroxyurea vs placebo

Serious adverse events · people with sickle cell disease

Hydroxyurea showed no clear difference in serious adverse events compared with placebo (low certainty).

1 finding from 1 review

Interventions for chronic kidney disease in people with sickle cell disease 2023 · Cochrane Headline outcomes only
RR 0.39 [0.13, 1.16]
1 study · 193 participants
Low

Hydroxyurea vs placebo

All‐cause mortality · people with sickle cell disease

2 findings from 2 reviews · compare the 2 reviews

Interventions for chronic kidney disease in people with sickle cell disease 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 193 participants
Low
Hydroxyurea (hydroxycarbamide) for sickle cell disease 2022 · Cochrane Headline outcomes only
RR 0.65 [0.19, 2.27]
5 studies · 784 participants
Moderate

Hydroxyurea vs placebo

Quality of life · people with sickle cell disease

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for chronic kidney disease in people with sickle cell disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Angiotensin‐converting enzyme inhibitors vs placebo

Reduction or prevention of kidney disease progression · people with sickle cell disease

1 finding from 1 review

Interventions for chronic kidney disease in people with sickle cell disease 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 22 participants
Very low

Angiotensin‐converting enzyme inhibitors vs placebo

Serious adverse events · people with sickle cell disease

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for chronic kidney disease in people with sickle cell disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Angiotensin‐converting enzyme inhibitors vs placebo

All‐cause mortality · people with sickle cell disease

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for chronic kidney disease in people with sickle cell disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Angiotensin‐converting enzyme inhibitors vs placebo

Quality of life · people with sickle cell disease

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for chronic kidney disease in people with sickle cell disease 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Angiotensin‐converting enzyme inhibitors vs vitamin C

Reduction or prevention of kidney disease progression · children with sickle cell anaemia and microalbuminuria

1 finding from 1 review

Interventions for chronic kidney disease in people with sickle cell disease 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 170 participants
Very low

Full‐mouth ultrasonic scaling plus photodynamic therapy vs full‐mouth ultrasonic scaling alone

Change in class of malocclusion · people with thalassaemia (any age)

The review found no eligible studies for this question.

1 finding from 1 review

Treatment of dental and orthodontic complications in thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Full‐mouth ultrasonic scaling plus photodynamic therapy vs full‐mouth ultrasonic scaling alone

Resolution or reduction in severity of any other dental complication: reduction in DMFT index · people with thalassaemia (any age)

The review found no eligible studies for this question.

1 finding from 1 review

Treatment of dental and orthodontic complications in thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found